ESR/EIBALL Subcommittee Report

Recent meeting held on March 3, 2016 during ECR Meeting in Vienna, Austria

Some key topics of discussion:

**Update on Collaboration with EORTC:**
- Approval by EORTC leadership to have two imaging liaisons representatives always included on each strategy committee of the EORTC disease oriented groups (DOGs) as *ex officio* members to influence upstream new clinical trials and include advanced imaging. Thus, the imaging component could be discussed at an early stage to ensure adequate support when imaging is used as a primary endpoint.
- Three EIBALL SC members are active members of the EORTC Imaging Group (one as vice-chair, one as a secretary and one as the former president). The next meeting of the EORTC Imaging Group takes place April 11, 2016.
- Collaboration on EORTC-1423-IG-GITCG: *Evaluation of diffusion-weighted MRI in patients with resectable liver metastases from colorectal cancer treated with preoperative therapy*. EIBALL and QIBA were both involved in this study using DWI as a primary endpoint, and it is anticipated a manuscript will be submitted describing the DWI phantom used for this multicentre trial.

**EIBALL** is collaborating with EORTC and ESOI on the training of future cancer imagers with regard to quantitative imaging with the joint educational courses on tumor staging and tumor therapy response assessment with hands-on courses and training in the implementation of imaging in clinical trials.

**NCI presentation on Advancing Imaging in Clinical Trials (L. Shankar, CIP)**

**Collaboration with the European Institute for Biomedical Imaging Research (EBIR):**
- Official application for joint initiative of EIBR and EIBALL was approved at the March 2016 EIBIR General Meeting.
- One of the first tasks: Update on the list of “core institutions” in Europe in which imaging biomarker development and studies are feasible and performed, and development of a network of collaborating institutions. An imaging facility database for potential sites in multicentre clinical trials will make the initiation phase of trials by EORTC more efficient.
- EIBIR would be the “operational arm”, while EIBALL would be the “strategic arm” as EIBALL is not a legal entity and can only play an advisory role.
- For now, EIBALL remains a subcommittee of the ESR Research Committee.

**Potential future EIBALL activity:** Accreditation of centres for certain quality criteria (similar to EANM) => potential collaboration with QIBA.
Potential EIBALL – QIBA collaboration on standardization of MR ASL (arterial spin labeling):
  • Xavier Golay/Gold Standard Phantoms proposal.
  • Due to limited resources of QIBA, EIBALL suggests the formation of a “European Task Force on ASL” within the QIBA PDF-MRI Biomarker Committee.

Other EIBALL contributions to projects, including IMI-TRISTAN Project applications, EU Cost Project, MR Fingerprinting, etc.

Report submitted by Professor Siegfried Trattnig
April 2016